Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price objective hoisted by equities research analysts at Barclays from $7.00 to $8.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target points to a potential upside of […]

Leave a Reply

Your email address will not be published.

Previous post Freshpet (NASDAQ:FRPT) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says
Next post Senior sleuths are the hottest thing in mysteries. Here are 5 who take a page from ‘Murder, She Wrote’